What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?

Asian Journal of Andrology

Volumn 13, Issue 4, 2011, Pages 624-625

  Namiki, Mikio ^a   Konaka, Hiroyuki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RISK; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PROSTATE CANCER; PROSTATECTOMY;

EID: 79960068050     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.74     Document Type: Article

References (9)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9. (Pubitemid 41095147)
2. DAmico AV, Whittington R, Malkowicz SB, Schultz D, Blank K et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74. (Pubitemid 28445094)
3. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006; 107: 1265-72. (Pubitemid 44452775)
4. Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys 1997; 37: 245-6. (Pubitemid 27138704)
5. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504.
6. Bolla M, de Reijke TM, van Tienhoven G, van den Bergh AC, Oddens J et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
7. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomized trial. Lancet Oncol 2011; 12: 451-9.
8. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-99. (Pubitemid 29284127)
9. Bittner N, Merrick GS, Wallner KE, Butler WM. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology 2008; 22: 995-1017.